Frontline masitinib combo delays progression in mCRPC with low metastatic involvement
Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
Relugolix does not significantly delay onset of castration resistance in prostate cancer
A secondary analysis of the phase 3 HERO trial showed that relugolix failed to significantly improve castration resistance–free survival versus standard leuprolide n patients with advanced prostate cancer.
Personalized medicine essential in crowded frontline RCC setting
Primo Lara, Jr, MD, highlights the multitude of available treatments in frontline renal cell carcinoma, and the need for individualized, multidisciplinary treatment in this setting.
Novel agent VERU-111 active in pretreated prostate cancer
The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.
Dual immunotherapy regimen shows early promise in urothelial carcinoma
Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.
Study of molecularly-guided therapy provides precision medicine insight in mRCC
The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.
2 Clarke Drive Cranbury, NJ 08512